Drug Search Results
More Filters [+]

Lerisetron

Alternative Names: lerisetron
Latest Update: 2013-08-02
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: 5-HT3 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Simbec Research
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Lerisetron

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Testicular Cancer|Seminoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

SIMBEC-RD526/21494

P3

Unknown status

Testicular Cancer|Seminoma

None

Recent News Events

Date

Type

Title